TG THERAPEUTICS, INC. Increase (Decrease) in Accounts Receivable
TG THERAPEUTICS, INC. (TGTX) reported Increase (Decrease) in Accounts Receivable of $95.94 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-05
- TG THERAPEUTICS, INC. increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was $9.52M, a 77.00% decline year-over-year.
- TG THERAPEUTICS, INC. increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was $86.42M, a 41.82% increase year-over-year.
- TG THERAPEUTICS, INC. increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was $40.24M, a 199.03% increase year-over-year.
- TG THERAPEUTICS, INC. increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was $33.87M, a 5.45% increase year-over-year.
- TG THERAPEUTICS, INC. increase (decrease) in accounts receivable for fiscal 2025 was $176.44M, a 125.94% increase from fiscal 2024.
- TG THERAPEUTICS, INC. increase (decrease) in accounts receivable for fiscal 2024 was $78.09M, a 52.84% increase from fiscal 2023.
- TG THERAPEUTICS, INC. increase (decrease) in accounts receivable for fiscal 2023 was $51.09M.
- TG THERAPEUTICS, INC. increase (decrease) in accounts receivable for fiscal 2022 was -$1.39M, a 200.00% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $9.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $95.94M 10-Q · filed 2026-08-05 | $136.18M derived: sum of 3 quarters · filed 2026-08-05 | $170.05M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $86.42M 10-Q · filed 2026-05-06 | $126.66M derived: sum of 2 quarters · filed 2026-05-06 | $160.53M derived: sum of 3 quarters · filed 2026-05-06 | $201.93M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $40.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $74.11M derived: sum of 2 quarters · filed 2026-02-27 | $115.51M derived: sum of 3 quarters · filed 2026-08-05 | $176.44M 10-K · filed 2026-02-27 |
| 2025-09-30 | $33.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $75.26M derived: sum of 2 quarters · filed 2026-08-05 | $136.20M 10-Q · filed 2025-11-05 | $149.66M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $41.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $102.33M 10-Q · filed 2026-08-05 | $115.79M derived: sum of 3 quarters · filed 2026-08-05 | $147.91M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $60.94M 10-Q · filed 2026-05-06 | $74.39M derived: sum of 2 quarters · filed 2026-05-06 | $106.51M derived: sum of 3 quarters · filed 2026-05-06 | $125.14M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $13.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $45.58M derived: sum of 2 quarters · filed 2026-02-27 | $64.20M derived: sum of 3 quarters · filed 2026-02-27 | $78.09M 10-K · filed 2026-02-27 |
| 2024-09-30 | $32.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $50.74M derived: sum of 2 quarters · filed 2025-11-05 | $64.63M 10-Q · filed 2025-11-05 | $76.41M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | $18.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | $32.52M 10-Q · filed 2025-08-08 | $44.29M derived: sum of 3 quarters · filed 2026-02-27 | $66.12M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-03-31 | $13.89M 10-Q · filed 2025-05-09 | $25.66M derived: sum of 2 quarters · filed 2026-02-27 | $47.50M derived: sum of 3 quarters · filed 2026-02-27 | $56.36M derived: sum of 4 quarters · filed 2026-02-27 |
| 2023-12-31 | $11.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $33.61M derived: sum of 2 quarters · filed 2026-02-27 | $42.47M derived: sum of 3 quarters · filed 2026-02-27 | $51.09M 10-K · filed 2026-02-27 |
| 2023-09-30 | $21.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $30.70M derived: sum of 2 quarters · filed 2024-11-07 | $39.32M 10-Q · filed 2024-11-07 | $39.32M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $8.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $17.48M 10-Q · filed 2024-08-09 | $17.48M derived: sum of 3 quarters · filed 2025-03-03 | $17.40M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $8.62M 10-Q · filed 2024-05-06 | $8.62M derived: sum of 2 quarters · filed 2025-03-03 | $8.54M derived: sum of 3 quarters · filed 2025-03-03 | $7.72M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$88.00K derived: sum of 2 quarters · filed 2025-03-03 | -$902.00K derived: sum of 3 quarters · filed 2025-03-03 | -$1.39M 10-K · filed 2025-03-03 |
| 2022-09-30 | -$88.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | -$902.00K derived: sum of 2 quarters · filed 2023-11-06 | -$1.39M 10-Q · filed 2023-11-06 | -$1.38M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | -$814.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | -$1.30M 10-Q · filed 2023-08-04 | -$1.30M derived: sum of 3 quarters · filed 2024-02-29 | -$843.00K derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | -$487.00K 10-Q · filed 2023-05-08 | -$482.00K derived: sum of 2 quarters · filed 2024-02-29 | -$29.00K derived: sum of 3 quarters · filed 2024-02-29 | $131.00K derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $5.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $458.00K derived: sum of 2 quarters · filed 2024-02-29 | $618.00K derived: sum of 3 quarters · filed 2024-02-29 | $1.39M 10-K · filed 2024-02-29 |
| 2021-09-30 | $453.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $613.00K derived: sum of 2 quarters · filed 2022-11-09 | $1.38M 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $160.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $931.00K 10-Q · filed 2022-08-09 | ||
| 2021-03-31 | $771.00K 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | $0.00 10-K · filed 2022-03-01 | |||
| 2019-12-31 | $0.00 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |